Abstract
Efficacy and safety data of third-line antiretroviral (ARV) regimens in adolescents are limited. This study enrolled HIV-infected Thais who were treated with third-line regimens consisting of darunavir/ritonavir (DRV/r), etravirine (ETR), tipranavir/ritonavir or raltegravir. Fifty-four adolescents 2-17 years of age were enrolled from 8 sites and followed for 48 weeks. Reasons for switch were second-line failure (n = 44) and toxicity to second-line regimens (n = 10). At switching to third-line ARV, the median age (interquartile range) was 14.3 (12.4-15.4) years. Genotypes at time of second-line failure (n = 44) were M184V (77%), ≥4 thymidine analogue mutations (25%), non-nucleoside reverse transcriptase inhibitor-resistant associated mutation (RAM) (80%), ETR-RAM score ≥4 (14%), any lopinavir-RAM (59%) and ≥1 major DRV-RAM (41%). The third-line regimens had a median of 4 (min-max, 4-6) drugs and included ETR/DRV/r (43%), DRV/r (33%), ETR (17%), tipranavir/ritonavir (2%) or raltegravir/DRV/r/ (4%). The median CD4 (interquartile range) increased from 16% (12-21) at third-line switch to 21% (18-25) and 410 (172-682) to 607 (428-742) cells/mm at 48 weeks (P < 0.001). HIV RNA declined from 3.9 (2.9-4.9) to 1.6 (1.6-3.0) log10 copies/...Continue Reading
References
Apr 17, 2007·Lancet·Beatriz GrinsztejnUNKNOWN Protocol 005 Team
Jul 10, 2007·Lancet·Adriano LazzarinBrian Woodfall
Jul 10, 2007·Lancet·José Valdez MadrugaUNKNOWN TITAN study group
Aug 30, 2008·AIDS·Juan C SalazarUNKNOWN PACTG 1051/BI Study Team
Aug 6, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Arkaitz ImazEsteban Ribera
Aug 6, 2009·The Pediatric Infectious Disease Journal·Podjanee JittamalaVirat Sirisanthana
Sep 3, 2009·AIDS·Stéphane BlancheSabrina Spinosa-Guzman
Oct 14, 2009·AIDS·Isabelle ThuretStéphane Blanche
Jan 7, 2010·AIDS·Johan VingerhoetsGastón Picchio
Apr 1, 2010·Current HIV Research·John D BaxterPeter J Piliero
Apr 19, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Margaret P RhoadsE G Hermione Lyall
May 12, 2011·AIDS Research and Human Retroviruses·Gaston PicchioJames Witek
Oct 27, 2011·AIDS Research and Therapy·Torsak BunupuradahJintanat Ananworanich
Nov 28, 2012·PloS One·Brian C ZanoniMargaret E Feeney
Dec 12, 2012·The Journal of Infectious Diseases·Joseph J EronUNKNOWN VIKING Study Group
Sep 3, 2013·The Pediatric Infectious Disease Journal·Juan C SalazarJaromir Mikl
Oct 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sharon NachmanUNKNOWN International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team
Nov 13, 2013·AIDS Research and Therapy·Robert SebunyaGrace Ndeezi
Mar 5, 2014·HIV Medicine·G Tudor-WilliamsUNKNOWN PIANO study group
Mar 29, 2014·Journal of the International Association of Providers of AIDS Care·Olukemi Osinusi-AdekanmbiAnthony Amoroso
Jun 6, 2014·AIDS Patient Care and STDs·Jintana IntasanUNKNOWN PREDICT Study Group
Aug 3, 2014·Global Health Action·Samsuddin KhanPetros Isaakidis
Sep 16, 2014·PloS One·Carina CesarUNKNOWN Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)
Feb 27, 2015·The Pediatric Infectious Disease Journal·Avy ViolariFrank L Tomaka
Apr 25, 2015·AIDS Research and Therapy·Weerawat ManosuthiUNKNOWN Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group
Jun 27, 2015·AIDS Patient Care and STDs·Lindsay L GordonHelen Chun
Jul 23, 2015·AIDS Research and Human Retroviruses·Wasana PrasitsuebsaiAnnette H Sohn
Aug 6, 2015·The Pediatric Infectious Disease Journal·Rolando M VianiUNKNOWN P1093 Study Team
Sep 26, 2015·Journal of the Pediatric Infectious Diseases Society·Paola CostenaroCarlo Giaquinto
Oct 27, 2016·AIDS·Wolfgang StöhrUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Citations
Jul 31, 2018·Tropical Medicine & International Health : TM & IH·F FilyB Schramm
Mar 3, 2020·PloS One·Cleophas ChimbeteteOlivia Keiser
Mar 2, 2019·Current Infectious Disease Reports·J Nuttall, V Pillay
Jul 30, 2020·Journal of the International AIDS Society·Gabriela PattenUNKNOWN IeDEA
Dec 29, 2019·Scientific Reports·Mayada Faisal NabihAmrizal Muhammad Nur